The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions

Giampaolo Niccoli, E Grube, B Chevalier, P Smits, V Džavík, Tm Patel, As Mullasari, J Wöhrle, M Stuteville, C Dorange, U Kaul

Risultato della ricerca: Contributo in rivistaArticolo in rivista

48 Citazioni (Scopus)

Abstract

The SPIRIT V (A Clinical Evaluation of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions) study is a post-market surveillance experience of the XIENCE V (Abbott Vascular, Santa Clara, California) everolimus-eluting stent (EES) in patients with higher-risk coronary anatomy.
Lingua originaleEnglish
pagine (da-a)168-175
Numero di pagine8
RivistaJACC. Cardiovascular interventions
Volume4
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Aged
  • Angioplasty, Balloon, Coronary
  • Asia
  • Canada
  • Cardiovascular Agents
  • Coronary Artery Disease
  • Disease-Free Survival
  • Drug-Eluting Stents
  • Europe
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Product Surveillance, Postmarketing
  • Prospective Studies
  • Prosthesis Design
  • Registries
  • Risk Assessment
  • Risk Factors
  • Sirolimus
  • South Africa
  • Thrombosis
  • Time Factors
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions'. Insieme formano una fingerprint unica.

Cita questo